Frazer Supply CAS 936563-96-1 Best Ibrutinib Price Ibrutinib Powder

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Fra2145665
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >98%
• CAS No.: 936563-96-1
• Test Method: HPLC
• MOQ: 1kg
• Appearance: White Powder
• Shelf Life: 2 Years
• Storage: Cool Dry Place
• Delivery: Express 5-7 Days Arrive
• Sample: Available
• Application: Pharmaceutical Grade
• Molecular Weight: 440.5
• Transport Package: Foil Bag
• Specification: 1kg Per Foil Bag, 10 Bags Per Carton, 25 Kg Per Dr
• Trademark: Frazer
• Origin: China
• Production Capacity: 1000kg/Month

Product Description

High Quality API Ibrutinib CAS 936563-96-1 for Anti-Cancer

Description

Ibrutinib is an inhibitor of Bruton tyrosine kinase (BTK) for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL belong to B-cell non-Hodgkin's lymphoma, which is refractory and prone to relapse. The commonly used chemoimmunotherapy is not targeted, and grade 3 or 4 adverse reactions often occur. Ibrutinib can combine with BTK, which is necessary for the formation, differentiation, communication and survival of B lymphocytes, and irreversibly inhibit the activity of BTK, effectively inhibit the proliferation and survival of tumor cells. In addition, it is rapidly absorbed after oral administration, the maximum plasma concentration is reached 1 ~ 2h, and the adverse reactions are grade 1 or 2, which will become a new option for the treatment of CLL and MCL. On November 13, 2013, the U.S. food and drug administration (FDA) to accelerate the approved PharmaChemicalbookcyclics Johnson & Johnson company and the United States Imbruvica (common name: Ibrutinib) for the treatment of mantle cell lymphoma (MCL), a rare and aggressive blood cancer. Ibrutinib, an oral bruton tyrosine kinase (BTK) inhibitor, was granted breakthrough Therapy status by the FDA in February 2013 and was approved for MCL on November 13, 2013 and CLL on February 12, 2014, respectively. By selectively covalently binding to cys-481, the target protein Btk is irreversibly inhibited, thus effectively preventing tumor migration from B cells to lymphoid tissue suitable for tumor growth environment.

 

 

Function

Chronic lymphocytic leukemia (CLL) chroniclymphocyticleukemia, is due to form mature lymphocytes can't normal apoptosis, cloning of sexual reproduction in the lymphoid tissue instead of a chronic blood system of malignant tumor. CLL runs in families and is one of the more common forms of B-cell non-Hodgkin's lymphoma (NHL). Mantlecelllymphoma (MCL) is a rare b-cell NHL, accounting for about 5% to 10% of all NHL, and has both refractory and aggressive malignant lymphoma. MCL is not easy to diagnose. About 85% of patients are in stage at diagnosis. And easy to relapse, is the long-term survival of the lowest subtype of lymphoma. In the Chemicalbook bed, high fever and fatigue, enlarged spleen and lymph nodes, gastrointestinal involvement, and infiltration of the nervous system are common. The current first-line treatment for CLL is FCR, a combination of fludarabine (F), cyclophosphamide (C), and rituximab (R), which has a moderate efficacy, but progression-free survival (DFS) is 38%, and grade 3 or 4 adverse reactions occur frequently. MCL usually uses anthracyclines or drugs containing large doses of cytarabine, but most of them are not sensitive to conventional chemotherapy drugs. Although many drugs have been used for treatment, the overall survival of patients has not been significantly prolonged [5]. Although MCL was also treated with the combination of drugs and monoclonal antibodies, the incidence of infection was about 14%, and the incidence of grade 3 to 4 adverse reactions was as high as 87%. Therefore, feasible treatment options and highly effective and safe drugs are yet to be introduced.

Application

B cell antigen receptor (BCR) signaling pathway is a key driver of the growth and spread of many tumors. As an indispensable participant in BCR signal peptides, BTK plays an important role in the formation, differentiation, communication and survival of B lymphocytes. BTK is a signal peptide molecule recognized by BCR channel. When this signal peptide molecule crosses the receptor on the surface of B lymphocytes, the essential channels for the transport, chemotaxis and adhesion of B lymphocytes are activated, which facilitates the formation of B cell malignant tumors. Ibrutinib is a Chemicalbook small molecule inhibitor of BTK. It binds to cysteine residues (Cys-481) at the active site of BTK and irreversibly inhibits BTK activity, thus inhibiting the activation of BCR signaling pathway, and effectively preventing tumor migration from B cells to lymphoid tissue suitable for tumor growth. It can reduce the malignant proliferation of B cells and induce cell apoptosis, so as to play a role in treating CLL and MCL. Non-clinical studies have shown that ibrutinib inhibits the proliferation and survival of malignant B lymphocytes in vivo.